PE20080214A1 - Moleculas de anticuerpo que se unen a la il-17 humana - Google Patents

Moleculas de anticuerpo que se unen a la il-17 humana

Info

Publication number
PE20080214A1
PE20080214A1 PE2007000825A PE2007000825A PE20080214A1 PE 20080214 A1 PE20080214 A1 PE 20080214A1 PE 2007000825 A PE2007000825 A PE 2007000825A PE 2007000825 A PE2007000825 A PE 2007000825A PE 20080214 A1 PE20080214 A1 PE 20080214A1
Authority
PE
Peru
Prior art keywords
cdr
seq
antibody
antibody molecules
refers
Prior art date
Application number
PE2007000825A
Other languages
English (en)
Inventor
Stephen Edward Rapecki
Andrew George Popplewell
Ralph Adams
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of PE20080214A1 publication Critical patent/PE20080214A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN ANTICUERPO QUE INHIBE LA ACTIVIDAD DE LA INTERLEUQUINA 17 (IL-17) QUE COMPRENDE: A) UNA CADENA PESADA CUYO DOMINIO VARIABLE SE ENCUENTRA EN LA SEC ID Nº: 1 PARA CDR-H1, SEC ID Nº: 2 PARA CDR-H2 Y SEC ID Nº: 3 PARA CDR-H3; B) UNA CADENA LIGERA CUYO DOMINIO VARIABLE SE ENCUENTRA EN LA SEC ID Nº: 4 PARA CDR-L1, SEC ID Nº: 5 PARA CDR-L2 Y SEC ID Nº: 6 PARA CDR-L3. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DEL ANTICUERPO. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ENFERMEDAD DE CROHN, PSORIASIS
PE2007000825A 2006-06-29 2007-06-26 Moleculas de anticuerpo que se unen a la il-17 humana PE20080214A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612928.2A GB0612928D0 (en) 2006-06-29 2006-06-29 Biological products

Publications (1)

Publication Number Publication Date
PE20080214A1 true PE20080214A1 (es) 2008-04-08

Family

ID=36888319

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000825A PE20080214A1 (es) 2006-06-29 2007-06-26 Moleculas de anticuerpo que se unen a la il-17 humana

Country Status (14)

Country Link
US (2) US8057794B2 (es)
EP (1) EP2038305B1 (es)
JP (2) JP5693844B2 (es)
CN (1) CN101501072B (es)
AR (1) AR061538A1 (es)
BR (1) BRPI0713300A2 (es)
CA (1) CA2655874C (es)
CL (1) CL2007001840A1 (es)
EA (1) EA020113B1 (es)
ES (1) ES2614636T3 (es)
GB (1) GB0612928D0 (es)
PE (1) PE20080214A1 (es)
TW (1) TW200808829A (es)
WO (1) WO2008001063A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
MX2009001620A (es) 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CN104628855A (zh) 2008-05-05 2015-05-20 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
CA2737636A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
RU2015132478A (ru) * 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
BR112012008444A2 (pt) * 2009-10-10 2019-09-24 Eleven Biotherapeutics Inc proteína isolada, composição farmacêutica, métodos para modular uma resposta imune ou inflamatória em um sujeito, para tratar um distúrbio mediado po ir-17 em um sujeito e para preparar uma proteína recombinante, ácido nucleico isolado, e, célula hospedeira recombinante
ES2728115T3 (es) 2009-10-30 2019-10-22 Janssen Biotech Inc Antagonistas de IL-17A
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
AU2011285922B2 (en) * 2010-08-05 2016-06-16 Anaptysbio, Inc. Antibodies directed against IL-17
CN103429261A (zh) * 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
CA2823812C (en) 2011-01-14 2017-02-14 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
US9920110B2 (en) 2011-03-09 2018-03-20 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN104011223A (zh) 2011-11-21 2014-08-27 诺华股份有限公司 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
WO2013158821A2 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP4223312A1 (en) 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
AU2015313827C1 (en) 2014-09-10 2018-08-30 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
WO2017160587A1 (en) 2016-03-16 2017-09-21 Abeome Corporation Neutralizing monoclonal antibodies to il-25 and uses thereof
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
WO2018015880A1 (en) 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
WO2018050028A1 (zh) * 2016-09-14 2018-03-22 北京韩美药品有限公司 一种能够特异性地结合il-17a的抗体及其功能片段
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
EP3703819A1 (en) 2017-11-02 2020-09-09 Novartis AG Method of treating tendinopathy using interleukin-17 (il-17) antagonists
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
AU2020215795A1 (en) 2019-01-31 2021-07-29 Numab Therapeutics AG Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
AU2020347952A1 (en) 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
CN114728060A (zh) 2019-11-19 2022-07-08 诺华股份有限公司 使用白介素-17（il-17）拮抗剂治疗狼疮性肾炎的方法
CN114746444A (zh) 2019-12-06 2022-07-12 诺华股份有限公司 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
CN112390890B (zh) * 2020-11-06 2022-06-24 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2005001044A2 (en) 2003-05-29 2005-01-06 Angiogenix, Inc. Compositions related to pleiotrophin methods and uses thereof
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
SI1983000T1 (sl) * 2003-11-21 2015-12-31 Ucb Biopharma Sprl Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EA200701211A1 (ru) * 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
AU2006214473A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
CN101227857B (zh) 2005-06-29 2011-10-19 电脑医师有限公司 具有导电桥的传感器组件
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7838638B2 (en) 2005-12-13 2010-11-23 Eli Lilly And Company Anti-IL-17 antibodies
EP2377887A1 (en) 2006-03-10 2011-10-19 Zymogenetics Inc Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
MX2009001620A (es) 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products

Also Published As

Publication number Publication date
EP2038305A1 (en) 2009-03-25
CL2007001840A1 (es) 2008-01-18
CN101501072B (zh) 2013-10-30
AR061538A1 (es) 2008-09-03
JP2013252147A (ja) 2013-12-19
US20120129219A1 (en) 2012-05-24
EA200900040A1 (ru) 2009-06-30
EP2038305B1 (en) 2016-11-16
CN101501072A (zh) 2009-08-05
US8057794B2 (en) 2011-11-15
US20100086538A1 (en) 2010-04-08
WO2008001063A1 (en) 2008-01-03
CA2655874A1 (en) 2008-01-03
US8435761B2 (en) 2013-05-07
EA020113B1 (ru) 2014-08-29
ES2614636T3 (es) 2017-06-01
JP2009540855A (ja) 2009-11-26
JP5693844B2 (ja) 2015-04-01
BRPI0713300A2 (pt) 2012-04-17
TW200808829A (en) 2008-02-16
GB0612928D0 (en) 2006-08-09
CA2655874C (en) 2017-05-02

Similar Documents

Publication Publication Date Title
PE20080214A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
PE20070998A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-6-humana
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
PE20121645A1 (es) Composiciones y metodos para tratar trastornos inflamatorios
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
JP2018507220A5 (es)
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
NZ585559A (en) Humanized antibodies against tl1a
RU2011129204A (ru) Антитела против ангиопоэтина-2 человека
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20130159A1 (es) Anticuerpos anti-cd40
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
PE20040947A1 (es) MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
PE20131400A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20061166A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-17 humana
NZ596136A (en) Anti-cd100 antibodies and methods for using the same
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
PE20141547A1 (es) Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
PE20170687A1 (es) Proteinas de enlace a cd127
PE20141564A1 (es) Moleculas de union para bcma y cd3
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20120554A1 (es) Polipeptidos y metodo de tratamiento
PE20130214A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
PE20091474A1 (es) Anticuerpos monoclonales contra la proteina rgm a y sus usos

Legal Events

Date Code Title Description
FC Refusal